YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer

NCT07583160 · tracked via the Priya Life Science China tracker

Sponsor

Changhai Hospital

Phase

Phase 1

Started

2026-06-01

Last updated

2026-05-13

Condition(s) studied

Metastatic Castration-Resistant Prostate Cancer PatientsCastration-Resistant Prostate Cancer (CRPC)Prostate Neoplasms

Investigational drug(s) / intervention(s)

Autologous Neoantigen-Pulsed Dendritic Cell Vaccine

Autologous Neoantigen-Pulsed Dendritic Cell Vaccine: Personalized autologous dendritic cell vaccine manufactured from patient-derived peripheral blood mononuclear cells (PBMCs). Dendritic cells are differentiated ex vivo using GM-CSF and IL-4, loaded with patient-specific synthetic neoantigen peptides (identified via NGS sequencing of tumor tissue), and matured using TNF-α, IFN-γ, and PGE2. The vaccine is administered subcutaneously at 1-3 sites (axillary or inguinal lymph node regions) every 2 weeks for a total of 4 doses. Each injection site receives 0.3 mL cell suspension. Three sequential dose cohorts: 5×10⁶ cells (low), 1×10⁷ cells (medium), and 1.5×10⁷ cells (high) per dose.

Study summary

This phase I study tests a personalized cancer vaccine (Neo-DC) for men with advanced prostate cancer (metastatic castration-resistant prostate cancer, or mCRPC) that has continued to grow despite standard hormone therapies and other treatments.

The vaccine is custom-made for each participant using their own immune cells (dendritic cells) mixed with specific tumor markers (neoantigens) unique to their cancer. These neoantigens are identified through genetic sequencing of the patient's tumor. The goal is to help the body's immune system recognize and attack the cancer cells specifically.

The study will enroll approximately 9 to 18 men and will test three different dose levels to find the safest amount. Participants will receive the vaccine as an injection under the skin every two weeks for a total of 4 doses over an 8-week treatment period.

The main purpose is to evaluate the safety of this vaccine, determine the maximum tolerated dose, and identify any serious side effects. Researchers will also look at whether the vaccine helps lower PSA levels (a blood marker for prostate cancer), slows cancer growth, and stimulates an immune response against the tumor.

Participants will be monitored closely during treatment and followed for several months afterward to assess long-term safety and effects.

Eligibility

Sex

MALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Male, age ≥18 years, with life expectancy ≥6 months. * Histologically confirmed prostate adenocarcinoma with documented metastatic disease (bone, lymph nodes, or visceral organs) by recent whole-body MRI, bone scintigraphy (ECT), or PSMA-PET/CT. * Confirmed metastatic castration-resistant prostate cancer (mCRPC) with documented disease progression after ≥1 line of novel endocrine therapy (e.g., abiraterone or enzalutamide). * ECOG performance status 0-1. * Availability of tumor tissue (fresh biopsy or archival specimen) for neoantigen screening. * Willingness to undergo long-term follow-up. * Provision of signed informed consent form by participant or legally authorized representative prior to study procedures. * Willingness to undergo prostate biopsy if required for tissue acquisition. Adequate organ function as defined by laboratory values at screening: Absolute neutrophil count (ANC) \>1.5×10⁹/L; Platelet count \>100×10⁹/L; Hemoglobin \>90 g/L; Total bilirubin, ALT, and AST within normal laboratory limits; Serum creatinine \<133 μmol/L (or \<1.5 mg/dL); INR \<1.3 (or \<3.0 if on warfarin or other anticoagulants); Albumin \>30 g/L; Left ventricular ejection fraction (LVEF) ≥45% Negative for HIV, HBV (HBV DNA ≤500 IU/mL acceptable), and HCV (HCV RNA negative); No clinically significant ECG abnormalities. Exclusion Criteria: * History of other malignancies within the past 5 years (except non-melanoma skin cancer or carcinoma in situ with documented disease-free survival \>5 years). * Symptomatic central nervous system metastases. * Uncontrolled active or persistent infection requiring systemic therapy. * Systemic corticosteroid therapy within 4 weeks prior to enrollment (equivalent to \>20 mg/day prednisone). * Prior immunomodulatory therapy within 3 months, including but not limited to IL-2, CTLA-4 inhibitors, PD-1/PD-L1 inhibitors, CD40 agonists, or CD137 agonists (except adjuvant IFN-α for high-risk melanoma). * Prior investigational prostate cancer-targeted vaccine therapy or cellular therapy within 3 months. * Receipt of other investigational products within 2 months prior to enrollment. * Known, confirmed, or suspected autoimmune disease or immunosuppressive condition. * History of severe allergic reaction to any prior vaccination (for infectious disease prevention). * Major cardiovascular events within 6 months prior to first dose, including acute coronary syndrome, aortic dissection, or stroke; or presence of severe cardiovascular disease requiring clinical intervention. * Active autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus). * Receipt of live vaccines within 4 weeks prior to first study treatment or planned during the study period. * Uncontrolled hypertension (despite optimal medical management). * Substance abuse or any psychological condition that, in the investigator's judgment, may interfere with study participation or results. * Investigator's assessment of insufficient compliance or presence of other severe systemic diseases that would make the participant unsuitable for the study. * High tumor burden as assessed by imaging, deemed unsuitable by the investigator.

Primary outcome measure(s)

Incidence of Dose-Limiting Toxicities (DLTs) — From first dose through 60 days after the last dose (up to approximately 3 months)
Number of participants experiencing Dose-Limiting Toxicities (DLTs) during the first 4 weeks (following 2 doses) of treatment. This is evaluated per the 3+3 dose-escalation design to assess the safety and tolerability of the autologous neoantigen-pulsed dendritic cell vaccine (YS247) in mCRPC patients.
Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) — From first dose through 60 days after the last dose (up to approximately 3 months)
Number of participants experiencing treatment-emergent adverse events (TEAEs), including specifically Grade ≥3 TEAEs, serious adverse events (SAEs), and immune-related adverse events. The severity of all adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) — From first dose through 60 days after the last dose (up to approximately 3 months)
Determination of the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of the autologous neoantigen-pulsed dendritic cell vaccine (YS247). The MTD and RP2D will be determined based on the assessment of Dose-Limiting Toxicities (DLTs) observed during the dose-escalation phase.

Trial sites (1)

Facility	City	Region	Status
Shanghai Changhai Hospital	Shanghai	Shanghai Municipality

More Changhai Hospital trials in China

CAR-NK Cells (CL-NK-003) in Pancreatic Cancer Recruiting

Direct Visualization ERAT Versus Laparoscopic Appendectomy in Adults With Acute Uncomplicated Appendicitis Recruiting

Pre-Packaged Low-Residue Diet Assisting Bowel Preparation in Patients With Inflammatory Bowel Disease Recruiting

Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC) Recruiting

Metformin in Post Chronic Pancreatitis Diabetes Mellitus Recruiting

Other trials for the same condition

Novel Therapy Target in Metastatic Prostate Cancer Recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer Recruiting

A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer Enrolling by invitation

TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07583160 on ClinicalTrials.gov ↗ ← All trials in China